Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis
NCT ID: NCT01733316
Last Updated: 2024-12-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
41 participants
INTERVENTIONAL
2013-01-31
2017-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In cystinosis, the body builds up cystine. When taken regularly, the active ingredient of Cystagon® (cysteamine bitartrate) reduces cystine in the body. RP103 has the same active ingredient as Cystagon® and is designed to reduce cystine in a similar way that Cystagon® does. To decide if RP103 is better than Cystagon®, the study will look at two types of blood tests. One test is pharmacodynamics (PD), which measures the amount of white blood cell (WBC) cystine after taking study drug. WBC cystine is a laboratory test used to find out if cysteamine bitartrate is reducing cystine levels in the body. The second test is pharmacokinetics (PK), which measures the amount of cysteamine in the blood after taking the drug.
RP103 is different from Cystagon®: Instead of the cysteamine bitartrate being absorbed from the stomach, RP103 is designed to be absorbed from the small intestine. This may make the effects of the drug last longer, so that it can be taken twice a day instead of four times a day like Cystagon®.
Some cystinosis patients have bad breath (halitosis) when they take Cystagon®. Study participants who experience bad breath with Cystagon® will be asked if they would like to participate in an optional "halitosis substudy" to investigate this issue by collecting some extra PK blood samples.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All Participants
Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).
RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).
Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H.
RP103
Cystagon®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RP103
Cystagon®
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On a stable dose of Cystagon® at least 21 days prior to Screening
* WBC cystine level \> 1 nmol 1/2 cystine/mg of protein, on average over at least 2 measurements collected during the 2 years prior to Screening
* No clinically significant change in liver function tests, i.e. 1.5 times upper limit of normal (ULN) for alanine aminotransferase and aspartate aminotransferase, and/or 1.5 times ULN for total bilirubin, within 6 months prior to Screening
* No clinically significant change in renal function, i.e. estimated glomerular filtration rate (GFR) within 6 months prior to Screening
* Must have an estimated GFR \> 20 mL/minute/1.73m\^2 (using the equation from Schwartz 2009 J Am Soc Nephrol 20:629-647)
* Female subjects who are sexually active and of childbearing potential, i.e. not surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception from Screening through completion of the study. Acceptable forms of contraception for this study include hormonal contraceptives (oral, implant, transdermal patch, or injection) at a stable dose for at least 3 months prior to Screening, barrier (spermicidal condom or diaphragm with spermicide), intrauterine device, or a partner who has been vasectomized for at least 6 months.
* Subject or their parent or guardian must provide written informed consent, assent (where applicable), prior to participation in the study
Exclusion Criteria
* Current history of the following conditions or any other health issues that make it, in the opinion of the investigator, unsafe for study participation:
* Inflammatory bowel disease, if currently active, or prior resection of the small intestine;
* Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias, or poorly controlled hypertension) within 90 days prior to Screening;
* Active bleeding disorder within 90 days prior to Screening;
* History of malignant disease within 2 years prior to Screening
* Hemoglobin level of \< 9 g/dL at Screening or, in the opinion of the investigator, a hemoglobin level that would make it unsafe for study participation
* Known hypersensitivity to cysteamine and penicillamine
* Female subjects who are nursing, planning a pregnancy, or are known or suspected to be pregnant
* Subjects who, in the opinion of the investigator, are not able or willing to comply with study requirements.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
California Pacific Medical Center (CPMC) Research Institute
San Francisco, California, United States
Stanford University Medical School
Stanford, California, United States
Emory Children's Center
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Baylor College of Medicine / Texas Childrens Hospital
Houston, Texas, United States
University Hospital of Leuven
Leuven, , Belgium
Hospices Civils de Lyon
Lyon, , France
Hôpital Necker-Enfants Malades
Paris, , France
Hôpital Robert Debré
Paris, , France
Ospedale Pediatrico Bambino Gesù
Rome, , Italy
Radboud University Nijmegen Medical Center
Nijmegen, , Netherlands
Queen Elizabeth Hospital Birmingham
Birmingham, , United Kingdom
Great Ormond Street
London, , United Kingdom
Guy's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629-37. doi: 10.1681/ASN.2008030287. Epub 2009 Jan 21.
Related Links
Access external resources that provide additional context or updates about the study.
RP103 (marketed as PROCYSBI) is now approved by the US FDA for management of nephropathic cystinosis in patients 6 years and older.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-002773-64
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
RP103-07
Identifier Type: -
Identifier Source: org_study_id